1
|
Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship. Am J Surg Pathol 2016; 40:e94-e102. [PMID: 27740970 PMCID: PMC5106320 DOI: 10.1097/pas.0000000000000749] [Citation(s) in RCA: 264] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute collects data on cancer diagnoses, treatment, and survival for approximately 30% of the United States (US) population. To reflect advances in research and oncology practice, approaches to cancer control are evolving from simply enumerating the development of cancers by organ site in populations to including monitoring of cancer occurrence by histopathologic and molecular subtype, as defined by driver mutations and other alterations. SEER is an important population-based resource for understanding the implications of pathology diagnoses across demographic groups, geographic regions, and time and provides unique insights into the practice of oncology in the US that are not attainable from other sources. It provides incidence, survival, and mortality data for histopathologic cancer subtypes, and data by molecular subtyping are expanding. The program is developing systems to capture additional biomarker data, results from special populations, and expand biospecimen banking to enable cutting-edge cancer research and oncology practice. Pathology has always been central and critical to the effectiveness of SEER, and strengthening this relationship in this modern era of cancer diagnosis could be mutually beneficial. Achieving this goal requires close interactions between pathologists and the SEER program. This review provides a brief overview of SEER, focuses on facets relevant to pathology practice and research, and highlights the opportunities and challenges for pathologists to benefit from and enhance the value of SEER data.
Collapse
Affiliation(s)
- Máire A. Duggan
- Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - William F. Anderson
- Divisions of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
| | - Sean Altekruse
- Cancer Control and Populations Sciences, National Cancer Institute, Bethesda, Maryland, USA
| | - Lynne Penberthy
- Cancer Control and Populations Sciences, National Cancer Institute, Bethesda, Maryland, USA
| | - Mark E. Sherman
- Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
| |
Collapse
|
2
|
Zhang L, Ma T, Brozick J, Babalola K, Budiu R, Tseng G, Vlad AM. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer. Oncogene 2016; 35:5010-20. [PMID: 26973247 PMCID: PMC5023457 DOI: 10.1038/onc.2016.53] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Revised: 01/13/2016] [Accepted: 02/01/2016] [Indexed: 02/01/2023]
Abstract
Mucin1 (MUC1) is an epithelial glycoprotein overexpressed in ovarian cancer and actively involved in tumor cell migration and metastasis. Using novel in vitro and in vivo MUC1-expressing conditional (Cre-loxP) ovarian tumor models, we focus here on MUC1 biology and the roles of Kras activation and Pten deletion during cell transformation and epithelial-to-mesenchymal transition (EMT). We generated several novel murine ovarian cancer cell lines derived from the ovarian surface epithelia (OSE) of mice with conditional mutations in Kras, Pten or both. In addition, we also generated several tumor-derived new cell lines that reproduce the original tumor phenotype in vivo and mirror late stage metastatic disease. Our results demonstrate that de novo activation of oncogenic Kras does not trigger increased proliferation, cellular transformation or EMT and prevents MUC1 upregulation. In contrast, Pten deletion accelerates cell proliferation, triggers cellular transformation in vitro and in vivo and stimulates MUC1 expression. Ovarian tumor-derived cell lines MKP-Liver and MKP-Lung cells reproduce in vivo EMT and represent the first immune competent mouse model for distant hematogenous spread. Whole genome microarray expression analysis using tumor and OSE-derived cell lines reveals a 121 gene signature associated with EMT and metastasis. When applied to n=542 cases from the ovarian cancer TCGA dataset, the gene signature identifies a patient subset with decreased survival (p=0.04). Using an extensive collection of novel murine cell lines we have identified distinct roles for Kras and Pten on MUC1 and EMT in vivo and in vitro. The data has implications for future design of combination therapies targeting Kras mutations, Pten deletions and MUC1 vaccines.
Collapse
Affiliation(s)
- L Zhang
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.,Magee-Womens Research Institute, Pittsburgh, PA, USA
| | - T Ma
- Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
| | - J Brozick
- Magee-Womens Research Institute, Pittsburgh, PA, USA
| | - K Babalola
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA
| | - R Budiu
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.,Magee-Womens Research Institute, Pittsburgh, PA, USA
| | - G Tseng
- Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
| | - A M Vlad
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.,Magee-Womens Research Institute, Pittsburgh, PA, USA
| |
Collapse
|
3
|
Piqueret-Stephan L, Marcaillou C, Reyes C, Honoré A, Letexier M, Gentien D, Droin N, Lacroix L, Scoazec JY, Vielh P. Massively parallel DNA sequencing from routinely processed cytological smears. Cancer Cytopathol 2015; 124:241-53. [DOI: 10.1002/cncy.21639] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Revised: 10/03/2015] [Accepted: 10/05/2015] [Indexed: 11/07/2022]
Affiliation(s)
| | | | - Cécile Reyes
- Genomic Platform, Translational Research Department; Institut Curie; Paris France
| | - Aurélie Honoré
- Analyse Moléculaire, Modélisation et Imagerie de la maladie Cancéreuse (AMMICa) CNRS Unité Mixte de Service 3655, INSERM US23, Paris Sud University), Translational Research Laboratory; Gustave Roussy Villejuif France
| | | | - David Gentien
- Genomic Platform, Translational Research Department; Institut Curie; Paris France
| | - Nathalie Droin
- Gustave Roussy; Villejuif France
- Unit 1009, INSERM; Villejuif France
| | - Ludovic Lacroix
- Analyse Moléculaire, Modélisation et Imagerie de la maladie Cancéreuse (AMMICa) CNRS Unité Mixte de Service 3655, INSERM US23, Paris Sud University), Translational Research Laboratory; Gustave Roussy Villejuif France
- Department of Biopathology; Gustave Roussy Villejuif France
| | - Jean-Yves Scoazec
- Analyse Moléculaire, Modélisation et Imagerie de la maladie Cancéreuse (AMMICa) CNRS Unité Mixte de Service 3655, INSERM US23, Paris Sud University), Translational Research Laboratory; Gustave Roussy Villejuif France
- Department of Biopathology; Gustave Roussy Villejuif France
| | - Philippe Vielh
- Gustave Roussy; Villejuif France
- Unité Mixte de Recherche 981, INSERM; Villejuif France
- Analyse Moléculaire, Modélisation et Imagerie de la maladie Cancéreuse (AMMICa) CNRS Unité Mixte de Service 3655, INSERM US23, Paris Sud University), Translational Research Laboratory; Gustave Roussy Villejuif France
- Department of Biopathology; Gustave Roussy Villejuif France
| |
Collapse
|